BiotechTube

IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Neoplasms

Conditions

Gastrointestinal Neoplasms, Adenocarcinoma

Trial Timeline

Aug 30, 2017 → Mar 20, 2024

NCT ID
NCT02795988

About IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.

IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine. is a phase 1/2 stage product being developed by Imugene for Gastrointestinal Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT02795988. Target conditions include Gastrointestinal Neoplasms, Adenocarcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02795988Phase 1/2Completed

Competing Products

20 competing products in Gastrointestinal Neoplasms

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
52
Patritumab deruxtecanDaiichi SankyoPhase 1/2
41
DS-6157aDaiichi SankyoPhase 1
33
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
52
Naldemedine + PlaceboShionogiPhase 2
52
GemcitabineEli LillyPhase 1/2
41
OlaratumabEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 2
52
cetuximabEli LillyPhase 2
52
BBI503Sumitomo PharmaPhase 2
52
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
41
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
77
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
52
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
77
FamitinibJiangsu Hengrui MedicinePhase 2
52
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
77
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
77
EsomeprazoleAstraZenecaPhase 3
77
AZD2171AstraZenecaPhase 2
52

Other Products from Imugene

IMU-131 + Ramucirumab plus Paclitaxel + PembrolizumabPhase 2
44
Azer-cel + Fludarabine + Cyclophosphamide + IL-2Phase 1
25
CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy + CF33-CD19 IT Combination + CF33-CD19 IV Combination + Blinatumomab + HydroxyureaPhase 1
25
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 AntibodyPhase 1
25
CF33-hNIS + Pembrolizumab + Modified FOLFOXPhase 1
25